Data Sheet (Cat.No.T4674)

SB297006

Chemical Properties



CAS No. : 58816-69-6

Formula: C18H18N2O5

Molecular Weight: 342.35

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	SB297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ. It is at least 250-fold selective for CCR3 over a panel of other chemokine receptors. SB 297006 blocks CCR3-mediated calcium mobilization induced by eotaxin, eotaxin-2, and MCP-4 in transfected cells. It suppresses antigen-induced accumulation of Th2 lymphocytes and eosinophils in lungs of mice when delivered subcutaneously (100 mg/kg).
Targets(IC50)	CCR

Solubility Information

Solubility	DMSO: 150 mg/mL (438.15 mM),Sonication is recommended. H2O: < 0.1 mg/mL (insoluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.68 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.921 mL	14.6049 mL	29.2099 mL
5 mM	0.5842 mL	2.921 mL	5.842 mL
10 mM	0.2921 mL	1.4605 mL	2.921 mL
50 mM	0.0584 mL	0.2921 mL	0.5842 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Mori, A., Ogawa, K., Someya, K., et al. Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists. Int. Immunol. 19(8), 913-921 (2007).